The STAT piece “Pharma’s drug spending deflection” was published July 27, 2026, as the online version of the Health Care Inc. newsletter. The publicly available portion of the article opens with the claim that the pharmaceutical industry’s principal lobbying organization, PhRMA, wants the public and the press to overlook an observable rise in prescription drug spending. The article is presented as a STAT+ exclusive, and the remainder of the reporting is accessible only to subscribers who log in.
STAT’s site framing for the article includes navigation and links to related beats such as biotechnology, CMS, drug development, government agencies, insurance, and pharmaceuticals. The page also contains standard STAT subscription promotion and plan pricing information for STAT+.
In the available excerpt, the author characterizes a common practice of lobbying organizations: they regularly distribute news releases and prepared talking points aimed at shaping media coverage. The article asserts that, at the time of publication, PhRMA was focusing on persuading audiences to ignore an increase in prescription drug spending. Beyond that opening statement, the public portion of the story does not include the underlying evidence, examples of press materials, or responses from PhRMA.
The source explicitly frames these communications as an attempt to influence reporting. It notes the broader pattern—lobbying groups frequently send materials to journalists—but does not, in the excerpt provided, lay out the specific claims PhRMA is advancing, the data PhRMA cites, or independent analysis of spending trends.
This article is labeled a STAT+ exclusive; the site prompts readers to log in or subscribe to unlock the full story. The excerpt stops after introducing the issue and the assertion about PhRMA’s stance. Because the remainder of the reporting is behind the STAT+ paywall, the publicly visible content does not report details that would normally be included in full coverage: supporting data on prescription drug spending increases, examples of PhRMA communications, quotations from industry, government, or independent analysts, methodological notes, or any response from PhRMA.
Where the public excerpt is silent, those specifics were not reported in the available source material. The page makes clear that to obtain the complete article and any in-depth analysis, readers must subscribe to STAT+ or log in with an account.
The author is identified as Bob Herman, STAT’s Business of Health Care Reporter. The page supplies a brief bio: Herman covers financial aspects of U.S. health care, with reported beats including health insurance and hospitals, Medicare Advantage, opaque prescription drug benefits, and executive compensation in health care. Contact details provided on the page include an email address (bob.herman@statnews.com) and a Signal handle (bobjherman.09). Social links (X and LinkedIn) are also listed.
The article is described as the online version of STAT’s weekly Health Care Inc. newsletter; the page invites readers to sign up for that newsletter. STAT’s subscription offerings and plan pricing are displayed on the page alongside the article.
From the public excerpt, the central claim is that PhRMA is attempting to influence how journalists and the public view rising prescription drug spending by urging them to ignore the trend. The article situates this behavior within a general description of how lobbying organizations operate.
However, because the substantive portion of the reporting is behind the STAT+ paywall, the excerpt does not report—or provide—key supporting material: quantitative evidence of the spending rise referenced, specific examples of PhRMA communications or talking points, reactions from other stakeholders, or independent analysis. Those elements were not reported in the publicly available source content and therefore cannot be summarized here.
To read the full reporting, including any data, examples, and analysis the author used to substantiate the opening assertions, readers are directed by the page to subscribe to STAT+ and log in.